Substance Use Tools & Resources  

Read the Guide

A collection of tools and resources for providers, staff, and patients who offer or use services to address substance use. See the full environmental scan (PDF 0.69 MB) and resources collection (PDF 1.28 MB) in PDF format.

Displaying 1 - 10 of 117

Academic Detailing Services - Opioid Overdose Education & Naloxone Distribution (OEND)

The VA Opioid Overdose Education & Naloxone Distribution (OEND) Program aims to reduce harm and risk of life-threatening opioid-related overdose and deaths among Veterans. This resource hub includes implementation toolkits, patient & provider guides, overdose education & naloxone distribution vidoes, and additional related VA resources.
Format
Website
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Patients
Families
Source
U.S Department of Veterans Affairs (VA)
Year
Resource Type
Website

Considerations for Buprenorphine Initiation and Maintenance Care

This virtual public meeting which explored real-world experiences and scientific evidence for buprenorphine initiation strategies, as well as medication dosing and management during continued treatment across different care settings
Format
Webinar/Video
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Regan-Udall Foundation for the FDA
Year
Resource Type
Video

Opioid-Overdose Reduction Continuum of Care Approach (ORCCA): A Policymakers Guide to Implementing Evidence-Based Strategies that Address Opioid Overdose

This publication is intended to aid policymakers, communities, and key stakeholders in developing comprehensive, multi-system strategies that address the opioid crisis.
Format
Guide
Audience
Policymakers
Communities
Source
National Institutes of Health (NIH) HEAL Initiative
Year
Resource Type
PDF

Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl

These guidelines provide practical clinical practice-based guidance, based on available research combined with emerging clinical experience, on the use of buprenorphine in the treatment of individuals using fentanyl and other highly potent synthetic opioids.
Format
Report/Paper/Issue Brief
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Provider Clinical Support System (PCSS)
Year
Resource Type
PDF

SAMHSA Training Requirements (MATE Act) Resources

This SAMHSA page includes information on 2023 training requirements that eliminated the DATA waiver that was previously needed to prescribe buprenorphine and expanded the number of DEA-registered practitioners able to treat people with opioid use disorder.
Format
Website
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Substance Abuse and Mental Health Services Administration (SAMHSA)
Year
Resource Type
Website

The Role of Low-Threshold Treatment for Patients with Opioid Use Dusirder (OUD) in Primary Care

This Topic Brief provides an overview of what constitutes low-threshold treatment for patients with OUD, the state of the evidence and patient perspectives on low-threshold OUD treatment, and key steps and strategies for providing low-threshold treatment for patients with OUD in primary care settings.
Format
Report/Paper/Issue Brief
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Agency of Healthcare Quality and Research (AHRQ) Integration Academy
Year
Resource Type
Website

2022 National Drug Control Strategy

This inaugural National Strategy proposes bold, targeted, and consequential actions to bend the curve on overdose deaths in the immediate term and reduce substance use and its damaging consequences in the US over the longer term.

Format
Guide
Report/Paper/Issue Brief
Audience
Behavioral Health Providers
Communities
Medical Providers
Other Team Members
Policymakers
Source
The White House Executive Office of the President, Office of National Drug Control Policy (ONDCP)
Year
Resource Type
PDF

A Practical Research Agenda for Treatment Development for Stimulant Use Disorder - Meeting Summary: May 2022

This document summarizes a discussion from a workshop where experts examined the evidence for candidate endpoints and study design strategies for clinical trials of stimulant use disorder treatments.
Format
Report/Paper/Issue Brief
Audience
Medical Providers
Behavioral Health Providers
Other Team Members
Source
Reagan-Udall Foundation for the FDA (Food and Drug Administration)
Year
Resource Type
PDF